In the present study, the differences in MDR-TB risk between the types of anti-TNF agents were not clear, in contrast to previous studies showing that the risk for TB is higher in patients receiving anti-TNF monoclonal antibody therapy than those receiving soluble TNF receptor therapy (28, 29). This evidence concerns the gene TNF and tuberculosis.